Prospective Phase II Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes

International Journal of Radiation Oncology Biology Physics - Netherlands
doi 10.1016/j.ijrobp.2017.09.050
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Successful Phase 2 Trial of Ultrafocal Brachytherapy for Low/Intermediate Risk Prostate Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2017English

Erectile Function After Permanent 125I Prostate Brachytherapy for Localized Prostate Cancer

Basic and Clinical Andrology
Reproductive MedicineUrology
2013English

Permanent Prostate Brachytherapy Monotherapy With I-125 for Low- And Intermediate-Risk Prostate Cancer: Outcome in 966 Patients

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2015English

Sexual Function After Permanent Seed Implant Prostate Brachytherapy

Japanese Journal of Urology
Urology
2012English

Impact of Age on Quality-Of-Life Outcomes After Treatment for Localized Prostate Cancer

European Urology
Urology
2015English

Early Patient-Reported Outcomes in a Randomized Phase II Trial of HDR Monotherapy in Low and Intermediate Risk Prostate Cancer

Brachytherapy
Nuclear MedicineRadiologyImagingOncology
2016English

Health-Related Quality of Life After Radical Prostatectomy and Low-Dose-Rate Brachytherapy for Localized Prostate Cancer

Urologia Internationalis
Urology
2009English

Toxicity and Quality of Life Report of a Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) for Low- And Intermediate-Risk Prostate Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

Ultra-Hypofractionated Radiation Therapy for Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Is Safe and Effective: 5-Year Outcomes of a Phase II Trial

BJU International
Urology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy